公开(公告)号：US20190337921A1

公开(公告)日：2019-11-07

申请号：US16349508

申请日：2017-11-22

申请人： Eisai R&D Management Co., Ltd.

发明人： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux

IPC分类号： C07D401/06 ,  C07D209/08 ,  C07D401/14 ,  A61P35/00

摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US10851065B2

公开(公告)日：2020-12-01

申请号：US15713107

申请日：2017-09-22

申请人： Eisai R&D Management Co., Ltd.

发明人： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K31/55 ,  C07D231/56 ,  C07D403/12 ,  C07D471/14 ,  C07D403/06 ,  C07D401/06 ,  C07D401/14

摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US20200255415A1

公开(公告)日：2020-08-13

申请号：US16349479

申请日：2017-11-22

申请人： Eisai R&D Management Co., Ltd.

发明人： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux ,  Sudeep Prajapati ,  Dominic Reynolds ,  Morgan O'Shea ,  Thiwanka Samarakoon

IPC分类号： C07D413/14 ,  A61P35/00 ,  C07D231/56 ,  C07D401/10 ,  C07D401/14 ,  C07D401/12 ,  C07D413/12 ,  C07D403/10

摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US09796683B2

公开(公告)日：2017-10-24

申请号：US15167373

申请日：2016-05-27

申请人： Eisai R&D Management Co., Ltd.

发明人： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu

IPC分类号： A01N43/40 ,  A61K31/44 ,  C07D231/56 ,  C07D403/12 ,  C07D471/14 ,  C07D403/06 ,  C07D401/06 ,  C07D401/14

CPC分类号： C07D231/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D471/14

摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.